varubi- rolapitant tablet varubi- rolapitant injection, emulsion
glaxosmithline llc - rolapitant hydrochloride (unii: 57o5s1qsaq) (rolapitant - unii:nle429izuc) - rolapitant 90 mg - varubi® is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. varubi is contraindicated in patients: risk summary the limited data with varubi use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. in animal reproduction studies, there were no adverse developmental effects observed with oral administration of rolapitant in rats and rabbits during the period of organogenesis at doses up to 1.3 times and 2.9-times, respectively, the maximum recommended human dose (mrhd) [see data] . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defec
varubi- rolapitant tablet
tersera therapeutics llc - rolapitant hydrochloride (unii: 57o5s1qsaq) (rolapitant - unii:nle429izuc) - varubi® is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. varubi is contraindicated in patients taking cyp2d6 substrates with a narrow therapeutic index, such as thioridazine and pimozide. varubi can significantly increase the plasma concentrations of thioridazine and pimozide, which may result in qt prolongation and torsades de pointes [see warnings and precautions (5.1)] . varubi is contraindicated in pediatric patients less than 2 years of age because of irreversible impairment of sexual development and fertility observed in juvenile rats at clinically relevant dosages [see use in specific populations (8.4)] . risk summary the limited data with varubi use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. in animal reproduction studies, there were no
varuby
tesaro bio netherlands b.v. - rolapitant - vomiting; nausea; cancer - antiemetics and antinauseants, - prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.varuby is given as part of combination therapy.
varuby 90mg tablets
tesaro uk ltd - rolapitant hydrochloride monohydrate - tablet - 90mg
varuby 90 mg 2 comprimits recoberts
inapitant aprepitant 125mg hard capsules
intega sdn. bhd. - aprepitant -
inapitant aprepitant 80mg hard capsules
intega sdn. bhd. - aprepitant -
inapitant tri-pack capsule
intega pte ltd - aprepitant (125mg capsule); aprepitant (80mg capsule) - capsule - aprepitant (125mg capsule) 125.00mg; aprepitant (80mg capsule) 80.00mg
unistrain prrs lyophilisate and solvent for suspension for injection for pigs
laboratorios hipra s.a. - live attenuated prrsv, strain vp-046 bis - lyophilisate and solvent for suspension for injection - 10(3.5) - 10(5.5) cell culture infective dose 50/dose - porcine reproductive and respiratory syndrome (prrs) virus - pigs - immunological - live vaccine
thyrokare tablet
neogen corporation - levothyroxine sodium - tablet - 0.1mg - levothyroxine sodium 0.1mg - dogs